J Frontier Co.,Ltd.
2934・Growth Market・Foods
Medical Care Sales Business
Business built around two pillars: the medical DX platform "SOKUYAKU" and pharmaceutical D2C
| Period | Current | Previous | Change |
|---|---|---|---|
| Segment Revenue | ¥5,284 million (FY2026 full year, ending May 2026) | ¥5,735 million (FY2025 full year, ending May 2025) | ↓ |
| Segment Operating Income | ¥484 million (FY2026 full year, ending May 2026) | ¥508 million (FY2025 full year, ending May 2025) | ↓ |
| Segment EBITDA | ¥529 million (FY2026 full year, ending May 2026) | ¥551 million (FY2025 full year, ending May 2025) | ↓ |
| Unamortized Goodwill Balance | ¥94 million (end of FY2026, ending May 2026) | ¥110 million (end of FY2025, ending May 2025) | ↓ |
Business Details
Operates "SOKUYAKU," a medical platform providing online medical consultations, online medication guidance, and prescription drug home delivery on a one-stop basis, alongside mail-order (D2C) sales of proprietary brand pharmaceuticals including the Seikansen® Series (Boufutsushosanand Boi-ogi-to Tablets SX, etc.). The company is also diversifying revenue sources into the B2B domain, including the corporate benefits program "SOKUYAKU Benefit" and incorporation into school trip plans. In FY2026 (ending May 2026), a revision of system usage fee pricing led to higher usage unit prices, contributing to improved profitability.
Recent Overview
Both revenue and EBITDA declined year on year, but SOKUYAKU's profitability continued to improve
For the full year of FY2026 (ending May 2026), segment revenue was ¥5,284 million (down 7.9% year on year), and segment EBITDA was ¥529 million (down 4.0% year on year). The system usage fee price revision implemented in the prior period raised usage unit prices, improving profitability. Usage volumes also continued to build up for seasonal conditions such as colds, influenza, and hay fever. The company also created new revenue sources in the B2B domain, including expanded corporate adoption of SOKUYAKU Benefit and incorporation into school trip plans. In the fourth quarter, the company made advance advertising investments aimed at generating revenue in the following fiscal year.
Key Products
Growth Drivers
- Continued improvement in usage unit prices and profitability driven by the SOKUYAKU system usage fee price revision
- Expansion of SOKUYAKU user numbers (accumulation of usage volume for seasonal conditions such as colds, influenza, and hay fever)
- Strengthening of a stable revenue base through expanded corporate adoption of SOKUYAKU Benefit
- Creation of new B2B revenue sources, such as incorporation of SOKUYAKU into school trip plans
- Regulatory tailwinds from the FY2022 (Reiwa 4) medical fee schedule revision, including the increase in the initial online consultation fee and relaxation of medication guidance requirements
- Policy to prioritize profit growth exceeding revenue growth in FY2027 (ending May 2027), centered on the Medical Care Sales Business with the SOKUYAKU business as the growth driver
Risks
- Risk of rising customer acquisition cost (CPO) for new subscription customers in the pharmaceutical D2C business
- Risk of regulatory changes such as medical-related laws and medical fee schedule revisions
- Impairment risk related to the unamortized goodwill balance of ¥94 million (end of FY2026, ending May 2026)
- Intensifying competition with rival medical platforms for users and partner medical institutions
- Recoupment risk related to advance advertising investments made in the fourth quarter for the following fiscal year
- A one-time goodwill write-off (extraordinary loss of ¥435 million) occurred in the Healthcare Sales Business, indicating similar impairment risk potentially latent across the group as a whole
Last updated: August 26, 2025